Use of autoantibodies in breast cancer screening and diagnosis

References

• Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur. J. Cancer37, S4–S66 (2001).
   PubMed Web of Science ®Google Scholar
• Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973–1997. Int. J. Epidemiol.34, 405–412 (2005).
   PubMed Web of Science ®Google Scholar
• Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomised trial: the health insurance plan (HIP) of greater New York study. In: Screening for Breast Cancer. Day NE, Miller AB (Eds). Hans Huber, Toronto, Canada, 3–15 (1988).
   Google Scholar
• Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet359, 909–919 (2002).
   PubMed Web of Science ®Google Scholar
• Tabar L, Fagerberg G, Chen HH et al. Efficacy of breast cancer screening by age: new results from the Swedish two-county trial. Cancer75, 2507–2517 (1995).
   PubMed Web of Science ®Google Scholar
• Bjurstam N, Bjorneld L, Duffy SW et al. The Gothenburg breast cancer screening trial: preliminary results on breast cancer mortality for women aged 39–49. J. Natl Cancer Inst. Monogr.22, 53–55 (1997).
   Google Scholar
• Miller AB, To T, Baines CJ, Wall C. Canadian national breast screening study 2: 13 year results of a randomised trial in women aged 50–59 years. J. Natl Cancer Inst.92, 1490–1499 (2000).
   PubMed Web of Science ®Google Scholar
• Alexander FE, Anderson TJ, Brown HK et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet353, 1903–1908 (1999).
   PubMed Web of Science ®Google Scholar
• Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomised screening trials. J. Natl Cancer Inst.97, 1195–1203 (2005).
   PubMedGoogle Scholar
• Dershaw DD. Status of mammography after the digital imaging screening trial: digital versus film. Breast J.12, 99–102 (2006).
   PubMed Web of Science ®Google Scholar
• Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol.23, 8469–8476 (2005).
   PubMed Web of Science ®Google Scholar
• Molina R, Barak V, van Dalen A et al. Tumor markers in breast cancer – European Group on tumor Markers recommendations. Tumor Biol.26, 281–293 (2005).
   PubMed Web of Science ®Google Scholar
• Tan EM, Shi WM. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin. Exp. Immunol.134, 169–177 (2003).
   PubMed Web of Science ®Google Scholar
• Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J. Clin. Invest.108, 1411–1415 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson WH, Di Gennaro C, Hueber W et al. Autoantigen microarrays for multiplex characterisation of autoantibody responses. Nat. Med.8, 295–301 (2002).
   PubMed Web of Science ®Google Scholar
• Sahin U, Treci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA92, 11810–11813 (1995).
   PubMed Web of Science ®Google Scholar
• Chen Y-T, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC. Genomic cloning and localisation of CTAG. A gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet. Cell Genet.79, 237–240 (1997).
   PubMedGoogle Scholar
• Luo L-Y, Herrera I, Soosaipillai A, Diamandis EP. Identification of heat shock protein 90 and other proteins as tumor antigens by serological screening of an ovarian carcinoma expression library. Br. J. Cancer87, 339–343 (2002).
   PubMed Web of Science ®Google Scholar
• Fernández Madrid F, Tang N, Alansari H, Karvonen RL, Tomkiel JE. Improved approach to identify cancer-associated autoantigens. Autoimmun. Rev.4, 230–235 (2005).
   PubMed Web of Science ®Google Scholar
• Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage displayed cDNA libraries. Eur. J. Immunol.31, 716–725 (2001).
   PubMed Web of Science ®Google Scholar
• Hansen MH, Ostenstad B, Sioud M. Antigen-specific IgG antibodies in stage IV long-time survival breast cancer patients. Mol. Med.7, 230–239 (2001).
   PubMed Web of Science ®Google Scholar
• Crawford VL, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein in p53 in sera from patients with breast cancer. Int. J. Cancer30, 403–408 (1982).
   PubMed Web of Science ®Google Scholar
• Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res.51, 6304–6311 (1991).
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature352, 345–347 (1991).
   PubMed Web of Science ®Google Scholar
• Caron de Fromental C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom. Cancer4, 1–15 (1992).
   PubMed Web of Science ®Google Scholar
• Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res.52, 4168–4174 (1992).
   PubMed Web of Science ®Google Scholar
• Lubin R, Schlichtholz B, Bengoufa D et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes on human p53: distribution on primary structure and exposure on protein surface. Cancer Res.53, 5872–5876 (1993).
   PubMed Web of Science ®Google Scholar
• Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 response in cancer patients. Cancer Res.53, 3468–3471 (1993).
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res.60, 1777–1788 (2000).
   PubMed Web of Science ®Google Scholar
• Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl Acad. Sci. USA89, 3439–1442 (1992).
   PubMed Web of Science ®Google Scholar
• Brass N, Ràcz A, Bauer C, Heckel D, Sybrecht G, Meese E. Role of amplified genes in the production of autoantibodies. Blood93, 2158–2166 (1999).
   PubMed Web of Science ®Google Scholar
• Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science237, 178–182 (1987).
   PubMed Web of Science ®Google Scholar
• Guerin M, Barrois M, Terrier MJ, Speilmann M, Riou G. Over-expression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res.3, 21–31 (1988).
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire EL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin E, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Stern DF, Heffernan PA, Weinberg RA. P185 a product of the neu proto-oncogene is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol.6, 1729–1740 (1986).
   PubMed Web of Science ®Google Scholar
• Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an erbB-related gene encoding a 185,000 Mr tumor antigen. Nature312, 513–516 (1984).
   PubMed Web of Science ®Google Scholar
• Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells15, 1–8 (1997).
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell45, 649–657 (1986).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat.52, 65–77 (1998).
   PubMed Web of Science ®Google Scholar
• Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titre HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol.11, 3363–3367 (1997).
   Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med.3, 917–921 (1997).
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem.18, 11177–11182 (1998).
   Google Scholar
• Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol.152, 43–49 (1998).
   PubMed Web of Science ®Google Scholar
• Lu CD, Altieri DC, Tanigawa N. Expression of a novel anti-apoptosis gene, survivin correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res.58, 1808–1812 (1998).
   PubMed Web of Science ®Google Scholar
• Shankar SL, Mani S, O’Guin KN, Kanimalla ER, Agrawal S, Shafit Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and dependent pathways. J. Neurochem.79, 426–436 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res.6, 127–134 (2000).
   PubMed Web of Science ®Google Scholar
• Nasu S, Yagihashi A, Izawa A et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res.22, 1839–1843 (2002).
   PubMed Web of Science ®Google Scholar
• Rohayem J, Diestelkoetter P, Weigle B et al. Antibody responses to the tumor associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res.60, 1815–1817 (2000).
   PubMed Web of Science ®Google Scholar
• Yagihashi A, Ohmura T, Asanuma K et al. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta362, 125–130 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prevent.12, 136–143 (2003).
   PubMed Web of Science ®Google Scholar
• Satie AP, Rajpert-De Meyts E, Spagnoli GC et al. The cancer-testis gene, NY-ESO-1, is expressed in normal foetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ.Lab. Invest.82, 775–780 (2002).
   PubMed Web of Science ®Google Scholar
• Chen Y-T, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA94, 1914–1918 (1997).
   PubMed Web of Science ®Google Scholar
• Mashino K, Sadanaga N, Tanaka F et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer85, 713–720 (2001).
   PubMed Web of Science ®Google Scholar
• Sugita Y, Wada H, Fujita S et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res.64, 2199–2204 (2004).
   PubMed Web of Science ®Google Scholar
• Stockert E, Jäger E, Chen Y-T et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med.187, 1349–1354 (1998).
   PubMed Web of Science ®Google Scholar
• Heyderman E, Steele K, Ormerod MG. A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue. J. Clin. Pathol.32, 35–39 (1979).
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Jaeger W, Syzmendera JJ et al. On behalf of the European Group for Serum tumor Markers in Breast Cancer. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. Eur. J. Cancer35, 47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Lloyd KO, Burchell J, Kudryashov V, Yin BWT, Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines – demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem.271, 33325–33334 (1996).
   PubMed Web of Science ®Google Scholar
• Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. An enzyme linked immunosorbant assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol.19, 186–195 (1998).
   PubMed Web of Science ®Google Scholar
• Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti MUC1 antibodies as a favourable prognostic factor for pancreatic cancer. Int. J. Cancer103, 97–100 (2003).
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med.161, 589–594 (2000).
   PubMed Web of Science ®Google Scholar
• Graves CRL, Robertson JFR, Murray A, Price MR, Chapman CJ. Malignancy induced autoimmunity to MUC1: an initial characterization. J. Peptide Res.66, 357–363 (2005).
   PubMedGoogle Scholar
• Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favourably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol.18, 574–583 (2000).
   PubMed Web of Science ®Google Scholar
• Regele S, Vogl FD, Kohler T, Kreienberg R, Runnebaum IB. P53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Res.23, 761–764 (2003).
   PubMed Web of Science ®Google Scholar
• Brankin B, Skaar TC, Brotzman M, Trock B, Clarke R. Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol. Biomarkers Prevent.7, 1109–1115 (1998).
   PubMed Web of Science ®Google Scholar
• Jäger E, Stockert E, Zidianakis Z et al. Humoral immune responses of cancer patients against “cancer-testis” antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer84, 506–510 (1999).
   PubMed Web of Science ®Google Scholar
• Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br. J. Cancer82, 85–87 (2000).
   PubMed Web of Science ®Google Scholar
• Conroy SE, Sasieni PD, Fentiman I, Latchman DS. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur. J. Cancer34(6), 942–943 (1998).
   PubMed Web of Science ®Google Scholar
• Conroy SE, Gibson SL, Brunström G, Isenberg D, Luqmani Y, Latchman DS. Autoantibodies to 90kD heat shock protein in sera of breast cancer patients. Lancet345, 126 (1995).
   PubMedGoogle Scholar
• Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay J-Y, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br. J. Cancer94, 1066–1070 (2006).
   PubMed Web of Science ®Google Scholar
• Mischo A, Kubuschok B, Ertan K et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int. J. Cancer118, 696–703 (2006).
   PubMed Web of Science ®Google Scholar
• Megliorino R, Shi F-D, Peng X-X et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect. Prev.29, 241–248 (2005).
   PubMedGoogle Scholar
• Fernández-Madrid F, Tang N, Alansari H et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res.64, 5089–5096 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang J-T, Chan EKL, Peng X-X et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin. Immunol.100, 149–156 (2001).
   PubMed Web of Science ®Google Scholar
• Tomkiel JE, Alansari H, Tang N et al. Auto-immunity to the Mr 32,000 subunit of replication protein A in breast cancer. Clin. Cancer Res.8, 752–758 (2002).
   PubMed Web of Science ®Google Scholar
• Barbouche MR, Romain S, Avrameas S, Piana L, Martin PM. Prognostic significance of autoantibodies to laminin in the sera of breast cancer patients: a preliminary report. Eur. J. Clin. Chem. Clin. Biochem.32, 511–514 (1994).
   PubMedGoogle Scholar
• Dalifard I, Daver A, Larra F. Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors. Anticancer Res.19, 5015–5022 (1999).
   PubMed Web of Science ®Google Scholar
• Mudenda B, Green JA, Green B et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br. J. Cancer69, 1115–1119 (1994).
   PubMed Web of Science ®Google Scholar
• Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet345, 621–622 (1995).
   PubMed Web of Science ®Google Scholar
• Regidor PA, Regidor M, Callies R, Schindler AE. Detection of p53 autoantibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? Eur. J. Gynaecol. Oncol.17, 192–199 (1996).
   PubMedGoogle Scholar
• Willsher PC, Pinder SE, Robertson L et al. The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res.16, 927–930 (1996).
   PubMed Web of Science ®Google Scholar
• Lenner P, Wiklund F, Emdin SO et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer79, 927–932 (1999).
   PubMed Web of Science ®Google Scholar
• Regele S, Kohlberger P, Vogl FD, Böhm W, Kreienberg R, Runnebaum IB. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br. J. Cancer81, 702–704 (1999).
   PubMed Web of Science ®Google Scholar
• Metcalf S, Wheeler TK, Picken S, Negus S, Milner AJ. p53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res.2, 438–443 (2000).
   PubMedGoogle Scholar
• Sangrajrang S, Arpornwirat W, Cheirsilpa A et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect. Prev.27, 182–186 (2003).
   PubMedGoogle Scholar
• Robertson JFR, Chapman C, Cheung K-L et al. Autoantibodies in early breast cancer. J. Clin. Oncol. (ASCO Annual Meeting Proceedings), 23, 549 (2005).
   Google Scholar
• Trivers GE, De Benedetti VM, Cawley HL et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res.2, 1767–1775 (1996).
   PubMed Web of Science ®Google Scholar
• Folli F, Solimena M, Cofiell R et al. Autoantibodies to a 128-kD synaptic protein in three women with the stiff man syndrome and breast cancer. N. Engl. J. Med.328, 546–551 (1993).
   PubMed Web of Science ®Google Scholar
• Sullivan Pepe M, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst.93, 1054–1061 (2001).
   PubMed Web of Science ®Google Scholar